Food Healthcare Provider Patients Safety 
Pharma Marketing Network
MAY 3, 2023
However, pharmaceutical marketing is also regulated by several agencies to ensure that patients are not exposed to false or misleading information. In this article, we will explore the regulatory environment of pharmaceutical marketing and how companies are navigating it to balance patient safety and industry innovation.
European Pharmaceutical Review
SEPTEMBER 2, 2022
To ensure the safety of medicines post-regulatory approval, a risk management plan (RMP) is established. As does the US Food and Drug Administration (FDA): REMS Assessment: Planning and Reporting Guidance for Industry Draft Guidance. What are risk minimisation methods?
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Clarivate
MARCH 14, 2024
Over the past few years nitrosamines and nitrosamine impurities have been increasingly gaining the reputation of being high-risk containments in the food industry. The food sector has already initiated the publication of preliminary regulations aimed at restricting PFAS in packaging. [3].
Nixon Gwilt Law
APRIL 22, 2024
The rule aims to regulate and enhance the transparency, effectiveness, and safety of predictive DSIs used in healthcare settings, ensuring that these technologies are developed and managed responsibly. Effective: Ensures that DSIs achieve their intended outcomes, improving clinical decision-making and patient care.
Legacy MEDSearch
JULY 13, 2022
Food and Drug Administration (FDA) has granted Breakthrough Device Designation to the AccuCinch ® Ventricular Restoration System. This program is designed to ensure patients and healthcare providers have more timely access to these medical devices. Ancora Heart , Inc., An estimated 6.5 million U.S. An estimated 6.5
European Pharmaceutical Review
NOVEMBER 8, 2022
In the US, members of the public can request, through a Citizen Petition, that the US Food and Drug Administration (FDA) “take or refrain from taking” various administrative actions, including denying approval of generic and biosimilar drug applications. Citizen Petitions before the FDA. Measuring and rating biosimilar access. Conclusion.
European Pharmaceutical Review
JULY 20, 2023
Background on BCT legislation in the EU Every year EU patients are treated with 25 million blood transfusions, a million cycles of medically assisted reproduction, over 35,000 transplants of stem cells and hundreds of thousands of replacement tissues.
Expert insights. Personalized for you.
52 
Let's personalize your content